Research Groups and R&D Platforms: Target discovery
Research Group:
Targeting Myo10 filopodia to block cancer cell metastasis
Johanna Ivaska
johanna.ivaska[at]utu.fi
Department of Life Technologies,
University of Turku
Basic research, Biochemistry, Biomedicine, Cancer, Disease models, Drug target, Electron microscopy, High throughput imaging, Imaging, Imaging software, Molecular Biology, Molecular Cell Biology, Receptor, Signaling, Super-resolution imaging, Target discovery
Research Group:
SORL1-dependent regulation of receptor trafficking in human carcinomas
Johanna Ivaska
johanna.ivaska[at]utu.fi
Department of Life Technologies,
University of Turku
Basic research, Biochemistry, Biomedicine, Cancer, Disease models, Drug target, Electron microscopy, High throughput imaging, Imaging, Imaging software, Molecular Biology, Molecular Cell Biology, Receptor, Signaling, Super-resolution imaging, Target discovery
Research Group:
Genetically modified animal models for biomedical research
Fuping Zhang
fuping.zhang[at]utu.fi
Institute of Biomedicine,
University of Turku
Biomedicine, Biotechnology, Breast cancer, Clinical Medicine, Disease models, Endocrinology, Genetics, In Vitro Diagnostics, In Vivo Diagnostics, Molecular Biology, Molecular Cell Biology, Obesity, Ovarian cancer, Physiology, Prostate cancer, Reproductive Medicine, Target discovery
Research Group:
Nuclear Lamins and Human Disease
Pekka Taimen
pepeta[at]utu.fi
Institute of Biomedicine,
University of Turku
Ageing-related diseases, Antibodies, Basic research, Biomarker, Biomedicine, Cancer, Cardiovascular diseases, Clinical Medicine, Diagnostics, Disease models, Drug target, Electron microscopy, Genetics, Genomics, Imaging, Imaging software, Inherited diseases, Lung cancer, Molecular Biology, Molecular Cell Biology, Musculoskeletal disorders, Next-generation sequencing, Pathology, Personalized medicine, Prostate cancer, Signaling, Super-resolution imaging, Target discovery
Research Group:
Skin cancer and proteinase research group
Veli-Matti Kähäri
veli-matti.kahari[at]utu.fi
Department of Clinical Medicine,
University of Turku
Basic research, Biomarker, Clinical Medicine, Data mining, Diagnostics, Disease models, Drug target, In Vivo Diagnostics, Melanoma, Molecular Cell Biology, Molecular diagnostics, Next-generation sequencing, Nucleic acids, Pathology, Personalized medicine, Receptor, Signaling, Skin diseases, Squamous cell carcinoma, Target discovery
R&D Platform:
Auria Biobank
Auria Biobank is a hospital integrated clinical biobank operating in Turku. It is jointly owned by University of Turku and Hospital districts of Southwest Finland, Satakunta and Vaasa. The catchment population is the area is approximately 900 000 people. Auria biobank was authorized to operate in March 2014. The aim of Auria is to provide a research infrastructure for both academic investigators and for company R&D. Auria has ongoing biobank projects with most big Pharma companies as well as academic research groups.
Biobank research plays a key role, for example in promoting personalized medicine, understanding the underlying diseases, and examining the effectiveness of therapies. The results from biobank studies will return to the biobank to add value to samples and to be used in new studies.
Auria has a collection of over one million FFPE tissue samples and ongoing collection of tissue and blood samples. Clinical data generated as part of the diagnosis, treatment, and follow-up of the patients is obtained from the hospital’s electronic health record systems and can be linked to the samples. Clinical data is stored in the biobank sample and data register in an encoded anonymized manner, which protects the privacy of the sample donors while making it possible to link the data from all sources to individual patients.
Basic research, Target discovery
